Off-Label Drug Use in Pediatrics
The unapproved use of approved drugs, also called off-label use, with children is quite common. This is because pediatric dosage guidelines are typically unavailable, since very few drugs have been specifically researched and tested with children.When treating children, prescribers often adjust dosages approved for adults to accommodate a child’s weight. However, children are not just “smaller” adults. Adults and children process and respond to drugs differently in their absorption, distribution, metabolism, and excretion.Photo Credit: Getty ImagesChildren even respond differently during stages from infancy to adolescence. This poses potential safety concerns when prescribing drugs to pediatric patients. As an advanced practice nurse, you have to be aware of safety implications of the off-label use of drugs with this patient group.To PrepareReview the interactive media piece in this week’s Resources and reflect on the types of drugs used to treat pediatric patients with mood disorders.Reflect on situations in which children should be prescribed drugs for off-label use.Think about strategies to make the off-label use and dosage of drugs safer for children from infancy to adolescence. Consider specific off-label drugs that you think require extra care and attention when used in pediatrics.BELOW IS THE QUESTION————————-Write a 1-page narrative in APA format that addresses the following:Explain the circumstances under which children should be prescribed drugs for off-label use. Be specific and provide examples.Describe strategies to make the off-label use and dosage of drugs safer for children from infancy to adolescence. Include descriptions and names of off-label drugs that require extra care and attention when used in pediatrics.BELOW IS THE REQUIRED READING———————————-Learning ResourcesRequired Readings (click to expand/reduce)Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) St. Louis, MO: Elsevier.Chapter 9, “Drug Therapy in Pediatric Patients” (pp. 58—60)Corny, J., Lebel, D., Bailey, B., & Bussieres, J. (2015). Unlicensed and off-label drug use in children before and after pediatric governmental initiatives. The Journal of Pediatric Pharmacology and Therapeutics, 20(4), 316-328. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557722/This article highlights pediatric governmental initiatives to prevent unlicensed and off-label drug use in children. Review these initiatives and guidelines and how they might impact your practice as an advanced practice nurse.Panther, S. G., Knotts, A. M., Odom-Maryon, T., Daratha, K., Woo, T., & Klein, T. A. (2017). Off-label prescribing trends for ADHD medications in very young children. The Journal of Pediatric Pharmacology and Therapeutics, 22(6), 423-429. doi:10.5863/1551-6776-22.6.423.please make sure to use APA format 7th edition and add 5 references not more than 5 years old.Please make sure to go through the rubic.This paper must include title page, introduction,summary with appropriate citation and conclusion. Please make sure to use headings to indicate part of the question you are answering and also provide examples as indicated by the question. CORE SKILL: understanding WHY off-label prescribing in children is both ubiquitous and ethically fraught — and being able to state the safeguards that make it defensible.
THE STRUCTURAL EXPLANATION (this is the analytical core, and most papers skip it): children are pharmacologically distinct, but they have been systematically EXCLUDED from clinical trials for reasons that are themselves ethical — inability to consent, vulnerability, and the difficulty of justifying risk in a population that cannot benefit from research participation in the way adults can. THE RESULT IS AN ETHICAL PARADOX: protecting children from research risk exposed them to the far greater risk of untested prescribing. That sentence, or something like it, IS the thesis this assignment wants.
THE POLICY RESPONSE — know these by name, they demonstrate you did the reading: the FDA MODERNIZATION ACT and the BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA), which offer 6 months of PATENT EXCLUSIVITY as an INCENTIVE for pediatric studies; and the PEDIATRIC RESEARCH EQUITY ACT (PREA), which is a MANDATE requiring pediatric assessment for certain new drugs. Incentive plus mandate is the two-pronged structure — knowing the difference between the carrot and the stick is exactly the kind of specificity that earns marks.
WHY CHILDREN ARE NOT SMALL ADULTS — the pharmacology: neonates have immature hepatic enzymes and reduced protein binding (raising free drug fraction), and an immature blood-brain barrier; infants and young children often have HIGHER weight-adjusted metabolic capacity relative to adults (proportionally larger liver), so mg/kg dosing can UNDERdose if extrapolated naively; body water and fat fractions differ, changing volume of distribution; renal clearance matures over months. Growth and development add outcomes adults don’t have (growth velocity, cognitive development, bone density).
THE CAUTIONARY CASES worth citing: CHLORAMPHENICOL and “gray baby syndrome” (immature glucuronidation); the historical use of ASPIRIN in children and REYE’S SYNDROME; CODEINE deaths in children post-tonsillectomy from CYP2D6 ULTRARAPID metabolism (leading to FDA contraindication) — this last one is the perfect example because it ties pharmacogenomics, prodrug metabolism, and off-label pediatric use into a single fatal chain.
DRUGS COMMONLY USED OFF-LABEL IN CHILDREN: many psychotropics (SSRIs beyond approved ages, atypical antipsychotics, alpha-2 agonists for ADHD), PPIs in infants, ondansetron.
STRATEGIES TO MAKE IT SAFER — the practical recommendations section: use the BEST AVAILABLE EVIDENCE (pediatric formularies, Lexicomp, AAP guidance, published trials); weight-based dosing with independent double-checks; explicit INFORMED CONSENT that discloses off-label status and documents it; ASSENT from the child where developmentally appropriate; heightened monitoring and shorter follow-up intervals; reporting adverse events to MedWatch; and involving a pediatric clinical pharmacist.
THE ETHICS: beneficence vs. nonmaleficence under uncertainty; the ethics of research WITH children (assent, minimal risk, parental permission) versus the ethics of prescribing WITHOUT evidence — and the argument that we have historically had the balance backwards.
Collepals.com Plagiarism Free Papers
Are you looking for custom essay writing service or even dissertation writing services? Just request for our write my paper service, and we'll match you with the best essay writer in your subject! With an exceptional team of professional academic experts in a wide range of subjects, we can guarantee you an unrivaled quality of custom-written papers.
Get ZERO PLAGIARISM, HUMAN WRITTEN ESSAYS
Why Hire Collepals.com writers to do your paper?
Quality- We are experienced and have access to ample research materials.
We write plagiarism Free Content
Confidential- We never share or sell your personal information to third parties.
Support-Chat with us today! We are always waiting to answer all your questions.
